Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Mitochondrial remodeling in cardiovascular disease: Therapeutic potential

Hypertension Research volume 46, pages 542–543 (2023)Cite this article

In recent years, the mortality rate associated with cardiovascular diseases (CVDs) has consistently increased and has emerged as the primary cause of death worldwide. It is a serious threat to humans, especially in the western world. CVDs are multifactorial disorders including several conditions, such as hypertension, obesity, and diabetes. The patient’s lifestyle, smoking, and consumption of alcohol are the main risk factors for this disease. CVDs comprise several diseases of the heart and blood vessels, such as cardiac hypertrophy, cerebrovascular disease, coronary heart disease, rheumatic heart disease, heart failure, and other conditions. There are various cellular and molecular mechanisms underlying cardiac pathogenesis. Generally, the heart consumes high-energy molecules for its function, which utilizes large amounts of ATP molecules. These molecules are produced by mitochondria through an oxidative phosphorylation mechanism [1, 2].

Mitochondria are essential organelles that regulate a variety of key cellular activities, including ATP synthesis and immunological activation. A functioning mitochondrial network is required for cardiovascular function and tolerance of pathological stresses. A considerable amount of evidence suggests that mitochondrial dysfunction plays a significant role in the etiology of several cardiovascular diseases. Over the last two decades, tremendous effort has gone into developing medicines that precisely target mitochondria for the treatment of cardiovascular disease. Despite such significant research, no medicines designed specifically to modify mitochondrial processes are currently available for the clinical therapy of cardiovascular disease [3]. In this letter, we discuss the application of mitochondrial remodeling in the treatment of cardiovascular diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018;15:457–70.

    Article  CAS  Google Scholar 

  2. Paramasivam A, Priyadharsini JV. m6A RNA methylation in heart development, regeneration and disease. Hypertens Res. 2021;44:1236–7.

    Article  CAS  Google Scholar 

  3. Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14:238–50.

    Article  CAS  Google Scholar 

  4. Sun XQ, Zhang R, Zhang HD, Yuan P, Wang XJ, Zhao QH, et al. Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis. Hypertens Res. 2016;39:302–11.

    Article  CAS  Google Scholar 

  5. Garrido-Moreno V, Díaz-Vegas A, López-Crisosto C, Troncoso MF, Navarro-Marquez M, García L, Estrada M, et al. GDF-11 prevents cardiomyocyte hypertrophy by maintaining the sarcoplasmic reticulum-mitochondria communication. Pharm Res. 2019;146:104273.

    Article  CAS  Google Scholar 

  6. Ribeiro Junior RF, Dabkowski ER, Shekar KC, O Connell KA, Hecker PA, Murphy MP. MitoQ improves mitochondrial dysfunction in heart failure induced by pressure overload. Free Radic Biol Med. 2018;117:18–29.

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Centre for Cellular and Molecular Research, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India

    Kannan Balachander, Jayaseelan Vijayashree Priyadharsini & Arumugam Paramasivam

Authors
  1. Kannan Balachander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jayaseelan Vijayashree Priyadharsini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arumugam Paramasivam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arumugam Paramasivam.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balachander, K., Priyadharsini, J.V. & Paramasivam, A. Mitochondrial remodeling in cardiovascular disease: Therapeutic potential. Hypertens Res 46, 542–543 (2023). https://doi.org/10.1038/s41440-022-01098-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-022-01098-6

Keywords

Search

Advanced search

Quick links